MedTrace Logo

Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer

NCT04067986 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2020-09-29

No results posted yet for this study

Summary

The efficacy and safety of the use of Camrelizumab combined with Apatinib

Conditions

  • Colorectal Cancer Recurrent

Interventions

DRUG

Camrelizumab

Camrelizumab One course will last 28 days.Intravenous injection at a dose of 200 mg, q2w One course will last 28 days. Oral administration at a dose of 250 mg/d

DRUG

Apatinib

Apatinib One course will last 28 days.Oral administration at a dose of 250 mg, qd

Sponsors & Collaborators

  • Zhongshan Hospital Xiamen University

    lead OTHER

Principal Investigators

  • Li Xiao, Doctor · Zhongshan Hospital Xiamen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-20
Primary Completion
2020-09-23
Completion
2021-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04067986 on ClinicalTrials.gov